articleSep 27, 2025
Lifetech

5 Indiana Startups in the Life Sciences Industry to Watch

Looking for the top life sciences industry startups? Discover 5 innovative Indiana-based startups in biotech, diagnostics, and more poised for growth.

Indiana has long been a powerhouse in the life sciences sector, boasting a robust ecosystem that combines academic excellence from institutions like Purdue University and Indiana University with industry giants such as Eli Lilly and Company. According to a recent BioCrossroads report, the state led the nation as the largest exporter of life sciences products in 2024, generating $99 billion in economic activity. This momentum continues into 2025, fueled by innovative startups leveraging cutting-edge technologies in biotechnology, diagnostics, and therapeutics.

With supportive organizations like BioCrossroads and Plug and Play providing funding and collaboration opportunities, Indiana’s startups are attracting significant interest and are poised for breakthroughs. Here are five promising life sciences startups to watch, each addressing critical health challenges with novel approaches.

GET IN TOUCH

Ready to start your innovation journey?

5 Indiana startups in the life science industry making an impact:

1. On Target Laboratories: Illuminating cancer surgery

Founded in 2017 and headquartered in West Lafayette, On Target Laboratories is revolutionizing cancer surgery through targeted intraoperative molecular imaging agents. Their flagship product, CYTALUX (pafolacianine) injection, binds to cancer cells and fluoresces under near-infrared light, enabling surgeons to detect and remove tumors more precisely during procedures. This technology reduces the risk of leaving cancerous tissue behind, improving patient outcomes in ovarian and lung cancers.
As of 2025, the company has raised $115+ million across eight funding rounds, including early-stage investments from Genome & Company and others.  A major milestone came in January 2025, when the FDA expanded CYTALUX’s indication for lung cancer detection during surgery, building on its initial approval for ovarian cancer. On Target is expanding its pipeline to other cancers.

Why watch? In a market where surgical precision can mean the difference between remission and recurrence, On Target’s innovations could set new standards, attracting partnerships with major hospitals and further funding.

 

2. Amplified Sciences: Early detection of pancreatic cancer

Amplified Sciences, based in West Lafayette and spun out from Purdue University in 2020, focuses on ultra-sensitive diagnostic assays for early cancer detection. Their lead product is a molecular sensing platform that detects pancreatic cancer at the single-molecule level, addressing a disease with notoriously low survival rates due to late diagnosis. The technology uses proprietary reagents to amplify signals from biomarkers in bodily fluids, offering a non-invasive alternative to traditional biopsies.

The startup has raised $8 million+ to date, with investors including the NIH and OCA Ventures. In November 2024, they closed a seed round to advance clinical trials and regulatory approvals. At the ADLM 2025 conference in Chicago, Amplified presented first clinical data on an assay panel for grading dysplasia in high-risk pancreatic lesions, demonstrating high accuracy.

Why watch? Pancreatic cancer affects over 60,000 Americans annually, and Amplified’s platform is disease-agnostic, with potential expansions to other cancers. As they move toward FDA clearance, expect acquisitions or collaborations from big pharma.

 
Sustainable Solutions for a Healthier Healthcare System Report
Read Now

3. Syndeio Biosciences: Repairing synapses for brain health

Launched in 2025 and headquartered in Indianapolis, Indiana, Syndeio Biosciences is pioneering neurotherapeutics that target synaptic dysfunction in central nervous system (CNS) disorders like Alzheimer’s disease and depression. Their approach involves small molecules that enhance synaptic health, restoring neural connections impaired in “synaptopathies.” This precision medicine strategy aims to treat root causes rather than symptoms, drawing from advanced neuroscience research.

In a blockbuster debut, Syndeio emerged in May 2025 with over $90 million in funding from investors including Innoviva, Catalio Capital Management, and others. This capital supports their lead programs into clinical trials, focusing on Alzheimer’s and major depressive disorder. The company’s launch has generated buzz for its potential to fill gaps in CNS treatments, where current drugs often fail to halt progression.

Why watch? With the global CNS disorder market projected to exceed $130 billion by 2030, Syndeio’s synapse-targeted platform could disrupt entrenched players. Their rapid funding success signals strong investor confidence in 2025 breakthroughs.

 

4. BiomEdit: Microbiome innovation for animal health

Fishers/Greenfield-based BiomEdit, founded in 2022, engineers microbiome-based solutions to improve animal health and sustainability in agriculture. Their designer probiotics combat diseases in livestock, such as enteric infections in pigs and poultry, using synthetic biology to create targeted microbial therapeutics. This reduces antibiotic reliance, addressing antimicrobial resistance, a growing global concern.

In July 2025, BiomEdit closed an oversubscribed $18 million Series B with participation from Nutreco and Betagro Ventures. The funding advances their lead product, BE-10, into the final development phases. They’ve also secured USDA grants for biologics against Highly Pathogenic Avian Influenza.

Why watch? As food security and sustainable farming rise on agendas, BiomEdit’s platform could expand to human health applications, positioning Indiana as a leader in ag-biotech crossovers.

 

5. Modicus Prime: AI-driven quality control in biomanufacturing

Established in 2020 in La Porte, Modicus Prime is advancing AI software to automate biologics image analysis for pharmaceutical quality control. Their GxP-compatible platform enables real-time detection of contaminants and anomalies in manufacturing processes, reducing costs by up to 50-60x and preventing drug product failures. The company empowers biotech experts with self-service AI tools for in-house analysis.

Modicus Prime has raised over $3.5 million in total funding. In July 2024, they announced residency at Johnson & Johnson Innovation — JLABS @ TMC to accelerate commercialization. As of 2025, the company launched an AI image processing add-on in collaboration with eLabNext, enhancing electronic lab notebooks for life sciences workflows.

Why watch? With AI revolutionizing biopharma, Modicus Prime’s solutions address critical quality assurance gaps, potentially leading to strategic partnerships and expansions in 2025.


The bright future of Indiana’s life science industry

These startups exemplify Indiana’s vibrant life sciences landscape, where innovation meets investment to tackle pressing health issues. As they advance through clinical stages and commercialization in 2025, keep an eye on potential IPOs, acquisitions, and global impacts. With the state’s supportive infrastructure, the future looks bright for Indiana biotech.

GET IN TOUCH

Ready to start your innovation journey?
PLUG AND PLAY AROUND THE WORLD

Discover our global locations

We have a community of experts all over the world. We work as a bridge between Silicon Valley and the rest of the world, making innovation open to anyone, anywhere.

Sign up for our global newsletter